Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.20.2
Earnings (Loss) Per Common Share (Tables)
 3 Months Ended
Sep. 30, 2020
Earnings (Loss) Per Common Share  
Schedule of Earnings (loss) Per Share, Basic and Diluted

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

September 30, 

 

    

2020

    

2019

Basic and diluted numerator:

 

 

  

 

 

  

 

 

 

  

 

 

  

Net loss attributable to iBio, Inc. stockholders

 

$

(7,533)

 

$

(4,463)

Preferred stock dividends

 

 

(66)

 

 

(66)

Net loss available to iBio, Inc. stockholders

 

$

(7,599)

 

$

(4,529)

 

 

 

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

162,442

 

 

21,923

 

 

 

 

 

 

 

Per share amount

 

$

(0.05)

 

$

(0.21)

 

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

 

 

 

 

 

 

 

Three Months Ended

 

 

September 30, 

 

    

2020

    

2019

 

 

(in thousands)

Stock options

 

3,486

 

1,347

Restricted stock units

 

41

 

 —

Series A Preferred

 

 —

 

430

Series B Preferred

 

 —

 

6,428

Shares excluded from the calculation of diluted loss per share

 

3,527

 

8,205